![](/sites/default/files/2024-08/Tobacco%20Markets.jpg)
Tobacco Markets
Open to Everyone
Friday, January 24, 2025
12 - 10 p.m. ET
Through a long history of product manipulation and misinformation, the for-profit tobacco industry has attempted to evade tobacco control policies. How can tobacco regulators and policymakers better anticipate industry responses to new regulations? What lessons from business and economics might regulators employ to forecast the total effects of new tobacco restrictions. We discuss these questions in the context of the current tobacco landscape, including the potential ban of methanol cigarettes and the industry pivot towards e-cigarettes. More generally, we discuss the question of what should be expected to for-profit corporations with respect to the health implications of their products. Is the tobacco industry unique in its behavior in its behavior? Are there lessons from other industries that may guide tobacco regulators?
Panelists:
![](/themes/custom/hbhi/assets/img/person-placeholder.jpg)
Mitch Zeller, J.D., Former Director of the Center for Tobacco Products, FDA
![](/themes/custom/hbhi/assets/img/person-placeholder.jpg)
Barbara Schillo, Ph.D., Chief Research Officer, Truth Initiative
![](/themes/custom/hbhi/assets/img/person-placeholder.jpg)
David Levy, Ph.D., Professor of Oncology, Georgetown University.
Moderators:
![](/sites/default/files/inline-images/Darden_Michael_HBHI2021%20-%20Michael%20Darden_4.jpg)
Michael Darden, PhD, Associate Professor, Johns Hopkins University, Carey Business School
![](/sites/default/files/inline-images/Drope_Jeffrey_HBHI_Jeffrey%20Drope.jpg)
Jeffrey Drope, PhD, Research Professor, Johns Hopkins University, Bloomberg School of Public Health, HBS
The Hopkins Business of Health Initiative integrates the scholarship across Johns Hopkins University - through a partnership between the Carey Business School, Bloomberg School of Public Health, School of Nursing, and School of Medicine - around a shared vision of a healthier America, supported by an affordable and equitable, high-value health system. In pursuit of this vision, our work focuses on the role of business and incentives through rigorous, objective, non-partisan, interdisciplinary research. Learn more here.